{
    "xml": "<topic id=\"PHP98031\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/effentora\" basename=\"effentora\" title=\"Effentora\">\n<title>Effentora<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP98294\" outputclass=\"indicationsAndDose\" rev=\"1.14\" parent=\"/clinical-medicinal-product-information/effentora\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Breakthrough pain in patients receiving opioid therapy for chronic cancer pain</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using sublingual tablets</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 100&#8239;micrograms, then 100&#8239;micrograms after 30&#8239;minutes if required, dose to be adjusted according to response&#8212;consult product literature, no more than 2 dose units for each pain episode; max. 800&#8239;micrograms per episode of breakthrough pain; leave at least 4 hours between treatment of episodes of breakthrough pain during titration.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP98307\" outputclass=\"directionsForAdministration\" rev=\"1.11\" parent=\"/clinical-medicinal-product-information/effentora\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Place tablet between cheek and gum and leave to dissolve; if more than 1 tablet required, place second tablet on the other side of the mouth; tablet may alternatively be placed under the tongue (sublingually).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP98311\" outputclass=\"patientAndCarerAdvice\" rev=\"1.11\" parent=\"/clinical-medicinal-product-information/effentora\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients or carers should be given advice on how to administer <i>Effentora</i>\n<tm tmtype=\"reg\"/> buccal tablets.</p>\n<p>Patients should be advised not to eat or drink until the tablet is completely dissolved; after 30 minutes, if any remnants remain, they may be swallowed with a glass of water. Patients with a dry mouth should be advised to drink water to moisten the buccal mucosa before administration of the tablets; if appropriate effervescence does not occur, a switch of therapy may be advised.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP98314\" outputclass=\"nationalFunding\" rev=\"1.10\" parent=\"/clinical-medicinal-product-information/effentora\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised that <i>Effentora</i>\n<tm tmtype=\"reg\"/> buccal tablets should be restricted for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain, when other short acting opioids are unsuitable.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP98031",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/effentora",
    "basename": "effentora",
    "title": "Effentora",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Breakthrough pain in patients receiving opioid therapy for chronic cancer pain",
                        "html": "Breakthrough pain in patients receiving opioid therapy for chronic cancer pain"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using sublingual tablets"
                    ],
                    "textContent": "By mouth using sublingual tablets",
                    "html": "By mouth using sublingual tablets"
                },
                "adult": [
                    {
                        "textContent": "Initially 100 micrograms, then 100 micrograms after 30 minutes if required, dose to be adjusted according to response&#8212;consult product literature, no more than 2 dose units for each pain episode; max. 800 micrograms per episode of breakthrough pain; leave at least 4 hours between treatment of episodes of breakthrough pain during titration.",
                        "html": "<p>Initially 100&#8239;micrograms, then 100&#8239;micrograms after 30&#8239;minutes if required, dose to be adjusted according to response&#8212;consult product literature, no more than 2 dose units for each pain episode; max. 800&#8239;micrograms per episode of breakthrough pain; leave at least 4 hours between treatment of episodes of breakthrough pain during titration.</p>"
                    }
                ]
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Place tablet between cheek and gum and leave to dissolve; if more than 1 tablet required, place second tablet on the other side of the mouth; tablet may alternatively be placed under the tongue (sublingually).",
                "html": "<p>Place tablet between cheek and gum and leave to dissolve; if more than 1 tablet required, place second tablet on the other side of the mouth; tablet may alternatively be placed under the tongue (sublingually).</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients or carers should be given advice on how to administer Effentora buccal tablets.\n\nPatients should be advised not to eat or drink until the tablet is completely dissolved; after 30 minutes, if any remnants remain, they may be swallowed with a glass of water. Patients with a dry mouth should be advised to drink water to moisten the buccal mucosa before administration of the tablets; if appropriate effervescence does not occur, a switch of therapy may be advised.",
                "html": "<p>Patients or carers should be given advice on how to administer <i>Effentora</i>\n<tm tmtype=\"reg\"/> buccal tablets.</p><p>Patients should be advised not to eat or drink until the tablet is completely dissolved; after 30 minutes, if any remnants remain, they may be swallowed with a glass of water. Patients with a dry mouth should be advised to drink water to moisten the buccal mucosa before administration of the tablets; if appropriate effervescence does not occur, a switch of therapy may be advised.</p>"
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised that Effentora buccal tablets should be restricted for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain, when other short acting opioids are unsuitable.",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised that <i>Effentora</i> <tm tmtype=\"reg\"/> buccal tablets should be restricted for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain, when other short acting opioids are unsuitable.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}